ORBIMED ADVISORS LLC 13D and 13G filings for PMV Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-04 9:12 pm Sale | 2026-03-02 | 13D | PMV PHARMACEUTICALS INC PMVP | ORBIMED ADVISORS LLC | 0 0.000% | -4,975,291 (Position Closed) | Filing |
| 2025-10-27 5:12 pm Sale | 2025-10-23 | 13D | PMV PHARMACEUTICALS INC PMVP | ORBIMED ADVISORS LLC | 4,975,291 9.400% | -1,587,786 (-24.19%) | Filing |
| 2023-08-23 4:56 pm Sale | 2023-08-09 | 13D | PMV PHARMACEUTICALS INC PMVP | ORBIMED ADVISORS LLC | 6,563,077 13.500% | -26,253 (-0.40%) | Filing |
| 2022-04-01 5:06 pm Unchanged | 2022-03-29 | 13D | PMV PHARMACEUTICALS INC PMVP | ORBIMED ADVISORS LLC | 6,589,330 14.500% | 0 (Unchanged) | Filing |